Ulf Elbelt

Dr. Ulf Elbelt


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
UEUlf Elbelt
Ulf Elbelt
ATAlessia Trovato
Alessia Trovato
MKMichael Kloth
Michael Kloth
EGEnno Gentz
Enno Gentz
RFReinhard Finke
Reinhard Finke
JSJochen G. Schneider
Jochen G. Schneider
Context: Primary macronodular adrenal hyperplasia (PMAH) is a rare cause of Cushing's syndrome, which may present in the context of different familial multitumor syndromes. Heterozygous inactivating germline mutations of armadillo repeat containing 5 (ARMC5) have very recently been described as cause for sporadic PMAH. Whether this genetic condition also causes familial PMAH in association with other neoplasias is unclear. Objective: The aim of the present study was to delineate the molecular cause in a large family with PMAH and other neoplasias. Patients and Methods: Whole-genome sequencing and comprehensive clinical and biochemical phenotyping was performed in members of a PMAH affected family. Nodules derived from adrenal surgery and pancreatic and meningeal tumor tissue were analyzed for accompanying somatic mutations in the identified target genes. Results: PMAH presenting either as overt or subclinical Cushing's syndrome was accompanied by a heterozygous germline mutation in ARMC5 (p.A110fs*9) located on chromosome 16. Analysis of tumor tissue showed different somatic ARMC5 mutations in adrenal nodules supporting a second hit hypothesis with inactivation of a tumor suppressor gene. A damaging somatic ARMC5 mutation was also found in a concomitant meningioma (p.R502fs) but not in a pancreatic tumor, suggesting biallelic inactivation of ARMC5 as causal also for the intracranial meningioma. Conclusions: Our analysis further confirms inherited inactivating ARMC5 mutations as a cause of familial PMAH and suggests an additional role for the development of concomitant intracranial meningiomas.

1 December 2010 in Clinical Nutrition
Verified
Journal Article
Closed access
UEUlf Elbelt
Ulf Elbelt
TSTatjana Schuetz
Tatjana Schuetz
IHIsabelle Hoffmann
Isabelle Hoffmann
MPMatthias Pirlich
Matthias Pirlich
CSChristian Joseph Strasburger
Christian Joseph Strasburger
HLHerbert Lochs
Herbert Lochs

1 January 2014 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
THTobias Hofmann
Tobias Hofmann
UEUlf Elbelt
Ulf Elbelt
AAAnne Ahnis
Anne Ahnis
PKPeter Kobelt
Peter Kobelt
MRMatthias Rose
Matthias Rose
ASAndreas Stengel
Andreas Stengel
Irisin was recently identified as muscle-derived hormone that increases energy expenditure. Studies in normal weight and obese subjects reported an increased irisin expression following physical activity, although inconsistent results were observed. Increased physical activity in a subgroup of patients with anorexia nervosa (AN) complicates the course of the disease. Since irisin could account for differences in clinical outcomes, we investigated irisin levels in anorexic patients with high and moderate physical activity to evaluate whether irisin differs with increasing physical activity. Hospitalized female anorexic patients (n=39) were included. Plasma irisin measured by ELISA and locomotor activity were assessed at the same time. Patients were separated into two groups (n=19/group; median excluded): moderate and high activity (6331±423 vs. 13743±1047 steps/day, p0.05), whereas body weight-adjusted total energy expenditure (46.0±1.4 vs. 41.1±1.1 kcal/kg/d), metabolic equivalents (METs, 1.9±0.1 vs. 1.7±0.1 METs/d), body weight-adjusted exercise activity thermogenesis (EAT, 1.8±0.5 vs. 0.6±0.3 kcal/kg/d), duration of exercise (18.6±4.7 vs. 6.2±3.1 min/d) and body weight-adjusted non-exercise activity thermogenesis (21.6±1.0 vs. 18.8±0.8 kcal/kg/d) were higher in the high activity compared to the moderate activity group (p0.05). In conclusion, the current data do not support the concept of irisin being induced by exercise, at least not under conditions of severely reduced body weight like AN.

1 September 2013 in Current Opinion in Clinical Nutrition and Metabolic Care
Verified
Journal Article
Closed access
UEUlf Elbelt
Ulf Elbelt
THTobias Hofmann
Tobias Hofmann
ASAndreas Stengel
Andreas Stengel
The recently identified myokine, irisin has raised great expectations as a potential target in the conservative treatment of obesity. This review focuses on studies exploring the effects of irisin in humans. Peroxisome proliferator-activated receptor γ coactivator-1 α expression in skeletal muscles is induced by exercise followed by expression of the membrane protein fibronectin type III domain containing 5. After cleavage from fibronectin type III domain containing 5, irisin is secreted into blood increasing thermogenesis by browning of subcutaneous white/beige adipose tissue. Although clear-cut data have been reported in rodents, the thermogenic effect of irisin in humans remains controversial. The initially reported exercise-dependent increase of irisin in humans could not be confirmed in most studies. However, a robust finding in human studies is the association of irisin with BMI. The discovery of irisin provides more insight into exercise-induced browning of adipose tissue, and therefore leads to a better understanding of mechanisms underlying body weight regulation and further down the road possibly may lead to treatment strategies of diseases with greatly altered body weight such as obesity or anorexia nervosa.

1 June 2009 in European Journal of Endocrinology
Verified
Journal Article
Closed access
UEUlf Elbelt
Ulf Elbelt
SHStefanie Hahner
Stefanie Hahner
BABruno Allolio
Bruno Allolio
Objective: Current glucocorticoid replacement regimens fail to fully mimic physiologic cortisol secretion in patients with primary adrenal insufficiency. This may lead to changes in insulin requirement in patients with primary adrenal insufficiency and type 1 diabetes. Therefore, we assessed insulin requirement in patients with autoimmune polyendocrine syndrome type 2 (APS-2).Design and subjects: Ten females with primary adrenal insufficiency and type 1 diabetes (mean duration of type 1 diabetes 13±11 years and of primary adrenal insufficiency 11±9 years) were retrospectively assessed regarding insulin regimen and insulin dose adjustment. Data were compared with control patients matched for age, sex and duration of diabetes drawn from all patients with type 1 diabetes attending the diabetes outpatient clinics at the University Hospital Wuerzburg for a scheduled consultation.Results: Glycaemia was well controlled in both groups (mean HbA1c 6.99±0.81% in APS-2 patients versus 6.69±1.03% in control patients). The mean weight-adjusted daily dose of insulin was non-significantly higher in patients with APS-2 compared with control patients (0.69±0.35 IU/kg body weight versus 0.51±0.17 respectively). The mean insulin (IU)/carbohydrate-ratio for 10 g of carbohydrate in the morning was 1.9±1.0 and 1.4±0.5 respectively. However, the insulin/carbohydrate-ratios were significantly higher in the APS-2 patients both at noon (mean ratio 2.0±0.9 vs 1.1±0.5 in control patients) and in the evening (mean ratio 2.1±1.1 vs 1.3±0.5 respectively;P<0.05).Conclusions: Glucocorticoid replacement therapy in patients with primary adrenal insufficiency and type 1 diabetes leads to significant changes in insulin requirement compared with patients with type 1 diabetes only.

18 September 2018 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLCeline Sina Lehmann
Celine Sina Lehmann
THTobias Hofmann
Tobias Hofmann
UEUlf Elbelt
Ulf Elbelt
MRMatthias Rose
Matthias Rose
CCChristoph Correll
Christoph Correll
VHVerena Haas
Verena Haas
Increased physical activity (PA) affects outcomes in patients with anorexia nervosa (AN). To objectively assess PA patterns of hospitalized AN patients in comparison with healthy, outpatient controls (HC), and to analyze the effect of PA on Body Mass Index (BMI) change in patients with AN, we measured PA in 50 female patients with AN (median age = 25 years, range = 18–52 years; mean BMI = 14.4 ± 2.0 kg/m2) at the initiation of inpatient treatment and in 30 female healthy controls (median age = 26 years, range = 19–53 years; mean BMI = 21.3 ± 1.7 kg/m2) using the SenseWear™ armband. Duration of inpatient stay and weight at discharge were abstracted from medical records. Compared with controls, AN patients spent more time in very light-intensity physical activity (VLPA) (median VLPA = 647 vs. 566 min/day, p = 0.004) and light-intensity physical activity (LPA) (median LPA = 126 vs. 84 min/day, p < 0.001) and less time in moderate-intensity physical activity (MPA) (median MPA = 82 vs. 114 min/day, p = 0.022) and vigorous physical activity (VPA) (median VPA = 0 vs. 16 min/day, p < 0.001). PA and BMI increase were not associated in a linear model, and BMI increase was mostly explained by lower admission BMI and longer inpatient stay. In a non-linear model, an influence of PA on BMI increase seemed probable (jack knife validation, r2 = 0.203; p < 0.001). No direct association was observed between physical inactivity and BMI increase in AN. An altered PA pattern exists in AN patients compared to controls, yet the origin and consequences thereof deserve further investigation.